A double-blind phase III clinical trial (FLAURA) showed that osimertinib gave a significantly longer progression-free survival than other TKIs in advanced-NSCLC patients with previously untreated mutated EGFR [148]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.